{ "disease": "neuroblastoma", "label": "Neuroblastoma", "url": "https://usebiotransfer.org/disease/neuroblastoma/", "built": "2026-09-07", "facts_hash": { "answers": "e2a258a37f2d", "targets": "a2e4a1ae6814" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-07", "trials": "2026-09-07" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "MYCN", "ensembl": "ENSG00000134323", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "PR", "bucket": "Database Ubiquitination" } ] }, { "symbol": "ALK", "ensembl": "ENSG00000171094", "n_drug_entries": 12, "n_distinct_drugs": 11, "drugs": { "ALECTINIB": "APPROVAL", "ASP-3026": "PHASE_1", "BRIGATINIB": "APPROVAL", "CEP-37440": "PHASE_1", "CERITINIB": "APPROVAL", "CONTELTINIB": "PHASE_1_2", "CRIZOTINIB": "APPROVAL", "ENSARTINIB": "PHASE_3", "ENTRECTINIB": "APPROVAL", "LORLATINIB": "APPROVAL", "PLB1003": "PHASE_1" }, "approved": [ "ALECTINIB", "BRIGATINIB", "CERITINIB", "CRIZOTINIB", "ENTRECTINIB", "LORLATINIB" ], "n_approved": 6, "approved_for": { "ALECTINIB": [ "non-small cell lung carcinoma" ], "BRIGATINIB": [ "non-small cell lung carcinoma", "anaplastic large cell lymphoma" ], "CERITINIB": [ "non-small cell lung carcinoma" ], "CRIZOTINIB": [ "non-small cell lung carcinoma" ], "ENTRECTINIB": [ "non-small cell lung carcinoma" ], "LORLATINIB": [ "lymphoma", "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Phase 1 Clinical" } ] }, { "symbol": "GPC2", "ensembl": "ENSG00000213420", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "B4GALNT1", "ensembl": "ENSG00000135454", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "TERT", "ensembl": "ENSG00000164362", "n_drug_entries": 2, "n_distinct_drugs": 1, "drugs": { "IMETELSTAT": "APPROVAL" }, "approved": [ "IMETELSTAT" ], "n_approved": 1, "approved_for": { "IMETELSTAT": [ "anemia", "myelodysplastic syndrome" ] }, "tractability": [ { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "LIN28B", "ensembl": "ENSG00000187772", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [] }, { "symbol": "PHOX2B", "ensembl": "ENSG00000109132", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [] }, { "symbol": "CD276", "ensembl": "ENSG00000103855", "n_drug_entries": 2, "n_distinct_drugs": 2, "drugs": { "8H9 131I": "PHASE_1", "ENOBLITUZUMAB": "PHASE_2_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "AB", "bucket": "Advanced Clinical" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "L1CAM", "ensembl": "ENSG00000198910", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] } ], "trials": { "by_antigen": { "GD2": { "n": 118, "n_observational": 9, "n_active": 49, "n_withdrawn": 3, "trials": [ { "nct": "NCT01704716", "title": "High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)", "status": "RECRUITING", "last_update": "2020-10-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02559778", "title": "Pediatric Precision Laboratory Advanced Neuroblastoma Therapy", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126916", "title": "Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03294954", "title": "GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma", "status": "RECRUITING", "last_update": "2025-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03721068", "title": "Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04211675", "title": "NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab", "status": "RECRUITING", "last_update": "2025-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04221035", "title": "High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)", "status": "RECRUITING", "last_update": "2025-06-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05272371", "title": "Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease", "status": "RECRUITING", "last_update": "2022-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05400603", "title": "Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma", "status": "RECRUITING", "last_update": "2025-12-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05489887", "title": "Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05608148", "title": "Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05754684", "title": "Quadruple Immunotherapy for Neuroblastoma", "status": "RECRUITING", "last_update": "2025-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06013618", "title": "Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma", "status": "RECRUITING", "last_update": "2025-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06071897", "title": "Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma", "status": "RECRUITING", "last_update": "2023-10-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06172296", "title": "Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06450041", "title": "NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06485947", "title": "Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma", "status": "RECRUITING", "last_update": "2025-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06528496", "title": "N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06540963", "title": "Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06684639", "title": "A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma", "status": "RECRUITING", "last_update": "2024-12-20", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06836505", "title": "Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.", "status": "RECRUITING", "last_update": "2025-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06995872", "title": "Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07027748", "title": "Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma", "status": "RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07318831", "title": "Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07334301", "title": "A Multi-Arm, Platform Trial For Relapsed Neuroblastoma", "status": "RECRUITING", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07375563", "title": "Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma", "status": "RECRUITING", "last_update": "2026-01-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07502287", "title": "Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002458", "title": "Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission", "status": "COMPLETED", "last_update": "2013-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002560", "title": "Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma", "status": "COMPLETED", "last_update": "2013-06-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002634", "title": "Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma", "status": "COMPLETED", "last_update": "2013-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003022", "title": "Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer", "status": "COMPLETED", "last_update": "2013-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003023", "title": "Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer", "status": "COMPLETED", "last_update": "2013-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003750", "title": "Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors", "status": "COMPLETED", "last_update": "2014-08-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004110", "title": "Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma", "status": "COMPLETED", "last_update": "2013-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005576", "title": "Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma", "status": "COMPLETED", "last_update": "2013-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00026312", "title": "Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma", "status": "COMPLETED", "last_update": "2026-03-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00030719", "title": "Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma", "status": "UNKNOWN", "last_update": "2014-06-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00037011", "title": "Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma", "status": "COMPLETED", "last_update": "2013-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00040872", "title": "Multiple Therapies in Treating Patients With Advanced Neuroblastoma", "status": "COMPLETED", "last_update": "2013-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00072358", "title": "Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma", "status": "COMPLETED", "last_update": "2022-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00082758", "title": "hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma", "status": "COMPLETED", "last_update": "2015-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085930", "title": "Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients", "status": "COMPLETED", "last_update": "2026-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00089258", "title": "Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment", "status": "COMPLETED", "last_update": "2013-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00445965", "title": "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer", "status": "COMPLETED", "last_update": "2024-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00450307", "title": "Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma", "status": "COMPLETED", "last_update": "2013-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00450827", "title": "Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma", "status": "COMPLETED", "last_update": "2015-09-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00492167", "title": "Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma", "status": "COMPLETED", "last_update": "2022-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00743496", "title": "A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma", "status": "COMPLETED", "last_update": "2017-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00877110", "title": "Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma", "status": "COMPLETED", "last_update": "2019-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00911560", "title": "Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral \u03b2-glucan for High-Risk Neuroblastoma", "status": "COMPLETED", "last_update": "2026-08-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00969722", "title": "A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients", "status": "TERMINATED", "last_update": "2013-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01041638", "title": "Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma", "status": "COMPLETED", "last_update": "2026-06-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01183416", "title": "High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation", "status": "COMPLETED", "last_update": "2019-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01183429", "title": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma", "status": "COMPLETED", "last_update": "2019-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01183884", "title": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma", "status": "TERMINATED", "last_update": "2019-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01183897", "title": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow", "status": "COMPLETED", "last_update": "2019-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01334515", "title": "Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma", "status": "COMPLETED", "last_update": "2019-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01419834", "title": "Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01460901", "title": "Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma", "status": "COMPLETED", "last_update": "2019-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01526603", "title": "High Dose Chemotherapy and Autologous Transplant for Neuroblastoma", "status": "COMPLETED", "last_update": "2024-02-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01576692", "title": "Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma", "status": "COMPLETED", "last_update": "2018-11-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01592045", "title": "ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma", "status": "COMPLETED", "last_update": "2015-09-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01662804", "title": "Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors", "status": "COMPLETED", "last_update": "2021-05-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01701479", "title": "Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)", "status": "UNKNOWN", "last_update": "2020-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01704872", "title": "ch14.18/CHO Bridging Study", "status": "COMPLETED", "last_update": "2020-10-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01711554", "title": "Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01757626", "title": "Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01767194", "title": "Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma", "status": "COMPLETED", "last_update": "2022-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01822652", "title": "3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01857934", "title": "Therapy for Children With Advanced Stage Neuroblastoma", "status": "COMPLETED", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953900", "title": "iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02100930", "title": "Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma", "status": "COMPLETED", "last_update": "2020-02-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02107963", "title": "A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors", "status": "COMPLETED", "last_update": "2024-05-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02130869", "title": "A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas", "status": "COMPLETED", "last_update": "2017-12-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02169609", "title": "Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma", "status": "COMPLETED", "last_update": "2024-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02173093", "title": "Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma", "status": "UNKNOWN", "last_update": "2019-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02258815", "title": "CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma", "status": "COMPLETED", "last_update": "2023-12-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02307630", "title": "PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02308527", "title": "Activity Study of Bevacizumab With Temozolomide \u00b1 Irinotecan for Neuroblastoma in Children", "status": "COMPLETED", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02439788", "title": "3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA", "status": "WITHDRAWN", "last_update": "2017-06-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02573896", "title": "Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02641782", "title": "NB2013-HR German (GPOH) / Dutch (DCOG) Trial", "status": "TERMINATED", "last_update": "2022-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02650648", "title": "Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma", "status": "COMPLETED", "last_update": "2025-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02743429", "title": "Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma", "status": "UNKNOWN", "last_update": "2021-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02761915", "title": "A Phase I Trial of Anti-GD2 T-cells (1RG-CART)", "status": "COMPLETED", "last_update": "2021-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02765243", "title": "Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma", "status": "COMPLETED", "last_update": "2024-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02914405", "title": "Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02919046", "title": "Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children", "status": "UNKNOWN", "last_update": "2017-03-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03033303", "title": "A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma", "status": "COMPLETED", "last_update": "2025-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03189706", "title": "Study of Chemoimmunotherapy for High-Risk Neuroblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03209869", "title": "Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2", "status": "WITHDRAWN", "last_update": "2022-09-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03242603", "title": "Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells", "status": "UNKNOWN", "last_update": "2018-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03332667", "title": "MIBG With Dinutuximab +/- Vorinostat", "status": "COMPLETED", "last_update": "2025-04-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03363373", "title": "Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03373097", "title": "Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03635632", "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03786783", "title": "Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma", "status": "COMPLETED", "last_update": "2026-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03794349", "title": "Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03860207", "title": "Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers", "status": "TERMINATED", "last_update": "2023-09-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04238819", "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma", "status": "COMPLETED", "last_update": "2026-03-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04385277", "title": "Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04539366", "title": "Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial", "status": "SUSPENDED", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560166", "title": "Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma", "status": "TERMINATED", "last_update": "2024-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04637503", "title": "4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04751383", "title": "Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma", "status": "TERMINATED", "last_update": "2026-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04909515", "title": "Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.", "status": "WITHDRAWN", "last_update": "2022-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05130255", "title": "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2", "status": "TERMINATED", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05373901", "title": "Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma", "status": "COMPLETED", "last_update": "2024-10-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05421897", "title": "Rapid Administration Pilot for Infusing Dinutuximab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05782959", "title": "Phase 1 Study of BCD-245 in Subjects With Neuroblastoma", "status": "UNKNOWN", "last_update": "2023-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05990751", "title": "Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047535", "title": "Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.", "status": "NOT_YET_RECRUITING", "last_update": "2023-09-21", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06438614", "title": "A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma", "status": "COMPLETED", "last_update": "2024-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06948994", "title": "A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07261241", "title": "NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07437963", "title": "Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07537400", "title": "Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07688252", "title": "Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 28, "n_observational": 0, "n_active": 16, "n_withdrawn": 2, "trials": [ { "nct": "NCT03294954", "title": "GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma", "status": "RECRUITING", "last_update": "2025-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03721068", "title": "Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04211675", "title": "NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab", "status": "RECRUITING", "last_update": "2025-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05400603", "title": "Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma", "status": "RECRUITING", "last_update": "2025-12-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06450041", "title": "NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06684639", "title": "A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma", "status": "RECRUITING", "last_update": "2024-12-20", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06836505", "title": "Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.", "status": "RECRUITING", "last_update": "2025-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07375563", "title": "Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma", "status": "RECRUITING", "last_update": "2026-01-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07502287", "title": "Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085930", "title": "Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients", "status": "COMPLETED", "last_update": "2026-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01460901", "title": "Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma", "status": "COMPLETED", "last_update": "2019-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01822652", "title": "3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02107963", "title": "A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors", "status": "COMPLETED", "last_update": "2024-05-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02130869", "title": "A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas", "status": "COMPLETED", "last_update": "2017-12-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02173093", "title": "Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma", "status": "UNKNOWN", "last_update": "2019-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02439788", "title": "3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA", "status": "WITHDRAWN", "last_update": "2017-06-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02573896", "title": "Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02761915", "title": "A Phase I Trial of Anti-GD2 T-cells (1RG-CART)", "status": "COMPLETED", "last_update": "2021-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02765243", "title": "Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma", "status": "COMPLETED", "last_update": "2024-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02919046", "title": "Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children", "status": "UNKNOWN", "last_update": "2017-03-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03209869", "title": "Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2", "status": "WITHDRAWN", "last_update": "2022-09-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03242603", "title": "Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells", "status": "UNKNOWN", "last_update": "2018-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03373097", "title": "Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03635632", "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04539366", "title": "Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial", "status": "SUSPENDED", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04637503", "title": "4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05990751", "title": "Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06948994", "title": "A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "GD2", "dinutuximab", "naxitamab", "hu14.18", "3F8" ] }, "B7-H3": { "n": 13, "n_observational": 1, "n_active": 7, "n_withdrawn": 0, "trials": [ { "nct": "NCT04897321", "title": "B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05562024", "title": "TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma", "status": "RECRUITING", "last_update": "2023-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06500819", "title": "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172958", "title": "Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07358260", "title": "B7-H3.CD28Z.CART in Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07502287", "title": "Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00089245", "title": "Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer", "status": "TERMINATED", "last_update": "2023-12-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00582608", "title": "Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9", "status": "TERMINATED", "last_update": "2017-03-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00923351", "title": "Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma", "status": "COMPLETED", "last_update": "2018-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02982941", "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03275402", "title": "131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases", "status": "TERMINATED", "last_update": "2024-02-13", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04637503", "title": "4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04864821", "title": "Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor", "status": "UNKNOWN", "last_update": "2021-05-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 7, "n_observational": 0, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT04897321", "title": "B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06500819", "title": "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172958", "title": "Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07358260", "title": "B7-H3.CD28Z.CART in Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07502287", "title": "Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04637503", "title": "4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04864821", "title": "Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor", "status": "UNKNOWN", "last_update": "2021-05-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "B7-H3", "CD276", "omburtamab", "enoblituzumab", "8H9" ] }, "GPC2": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT07087002", "title": "GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults", "status": "RECRUITING", "last_update": "2026-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650749", "title": "GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT07087002", "title": "GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults", "status": "RECRUITING", "last_update": "2026-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650749", "title": "GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "GPC2", "glypican-2" ] }, "L1CAM": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02311621", "title": "Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02311621", "title": "Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "L1CAM", "CD171" ] } }, "by_drug": { "8H9 131I": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00089245", "title": "Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer", "status": "TERMINATED", "last_update": "2023-12-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ALECTINIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05770037", "title": "DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "CERITINIB": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02559778", "title": "Pediatric Precision Laboratory Advanced Neuroblastoma Therapy", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01742286", "title": "Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)", "status": "COMPLETED", "last_update": "2020-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02780128", "title": "Next Generation Personalized Neuroblastoma Therapy", "status": "TERMINATED", "last_update": "2026-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CRIZOTINIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00939770", "title": "Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma", "status": "COMPLETED", "last_update": "2020-06-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01121588", "title": "Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)", "status": "TERMINATED", "last_update": "2025-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01606878", "title": "Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma", "status": "COMPLETED", "last_update": "2024-01-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ENOBLITUZUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02982941", "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ENSARTINIB": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03213652", "title": "Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ENTRECTINIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02650401", "title": "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IMETELSTAT": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 2, "trials": [ { "nct": "NCT01916187", "title": "Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma", "status": "WITHDRAWN", "last_update": "2020-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02011126", "title": "Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors", "status": "WITHDRAWN", "last_update": "2018-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LORLATINIB": { "n": 2, "n_observational": 1, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT03126916", "title": "Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03107988", "title": "NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] } } } }